Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andy Pike

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 17, 2021
Impact of Interindividual Differences in Plasma Fraction Unbound on the Pharmacokinetics of a Novel Syk Kinase Inhibitor in Beagle DogsAndy Pike, Barry Jones, Roshini Markandu, et al.
Journal of Pharmaceutical Sciences|November 28, 2020
A Novel Method for Preventing Non-specific Binding in Equilibrium Dialysis Assays Using Solutol® as an AdditiveAbhishek Srivastava, Andy Pike, Beth Williamson, et al.
Journal of Medicinal Chemistry|April 24, 2025
In Vitro ADME Profiling of PROTACs: Successes, Challenges, and Lessons Learned from Analysis of Clinical PROTACs from a Diverse Physicochemical SpaceAbhishek Srivastava, Andy Pike, Magda Swedrowska, et al.
Drug Discovery Today|July 22, 2020
Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspectiveAndy Pike, Beth Williamson, Stephanie Harlfinger, et al.
Biopharmaceutics & Drug Disposition|September 4, 2018
The role of organic anion-transporting polypeptides and formulation in the clearance and distribution of a novel Na<sub>v</sub> 1.7 channel blockerAndy Pike, Neil J Flanagan, R Ian Storer, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 29, 2024
The Role of Intramolecular Reactions and Chemical Degradation in the Apparent Biotransformation Pathways of a Series of SYK InhibitorsBeatriz Calle, Bernard Barlaam, Coura Diène, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 4, 2006
Rat pharmacokinetics and pharmacodynamics of a sustained release formulation of the GABAA alpha5-selective compound L-655,708John R Atack, Andy Pike, Ashley Clarke, et al.
Nature Reviews. Chemistry|December 13, 2025
Lessons learned in linking PROTACs from discovery to the clinicAndy Pike, Esther C Y Lee, Iacovos N Michaelides, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 31, 2022
ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs)Kevin Beaumont, Andy Pike, Michael Davies, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 11, 2023
Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein DegradersLaurie P Volak, Heide Marika Duevel, Sara Humphreys, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 17, 2021
Impact of Interindividual Differences in Plasma Fraction Unbound on the Pharmacokinetics of a Novel Syk Kinase Inhibitor in Beagle DogsAndy Pike, Barry Jones, Roshini Markandu, et al.
Journal of Pharmaceutical Sciences|November 28, 2020
A Novel Method for Preventing Non-specific Binding in Equilibrium Dialysis Assays Using Solutol® as an AdditiveAbhishek Srivastava, Andy Pike, Beth Williamson, et al.
Journal of Medicinal Chemistry|April 24, 2025
In Vitro ADME Profiling of PROTACs: Successes, Challenges, and Lessons Learned from Analysis of Clinical PROTACs from a Diverse Physicochemical SpaceAbhishek Srivastava, Andy Pike, Magda Swedrowska, et al.
Drug Discovery Today|July 22, 2020
Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspectiveAndy Pike, Beth Williamson, Stephanie Harlfinger, et al.
Biopharmaceutics & Drug Disposition|September 4, 2018
The role of organic anion-transporting polypeptides and formulation in the clearance and distribution of a novel Na<sub>v</sub> 1.7 channel blockerAndy Pike, Neil J Flanagan, R Ian Storer, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 29, 2024
The Role of Intramolecular Reactions and Chemical Degradation in the Apparent Biotransformation Pathways of a Series of SYK InhibitorsBeatriz Calle, Bernard Barlaam, Coura Diène, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 4, 2006
Rat pharmacokinetics and pharmacodynamics of a sustained release formulation of the GABAA alpha5-selective compound L-655,708John R Atack, Andy Pike, Ashley Clarke, et al.
Nature Reviews. Chemistry|December 13, 2025
Lessons learned in linking PROTACs from discovery to the clinicAndy Pike, Esther C Y Lee, Iacovos N Michaelides, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 31, 2022
ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs)Kevin Beaumont, Andy Pike, Michael Davies, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 11, 2023
Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein DegradersLaurie P Volak, Heide Marika Duevel, Sara Humphreys, et al.
Pageof 3